Mozavaptan

Mozavaptan (CAS No.: 137975-06-5) is a benzodiazepine derivative that acts as a competitive vasopressin receptor antagonist, primarily targeting V1 and V2 receptors, with IC50 values of 1.2 μM and 14 nM, respectively. Its selectivity for the V2 receptor is approximately 85-fold higher than for the V1 receptor. In vivo, Mozavaptan antagonizes the antidiuretic effect of arginine vasopressin and is used in research on hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and congestive heart failure. In cell and animal models, Mozavaptan is commonly used to evaluate its effects on aquaporin regulation and electrolyte balance; the doses or concentrations used in experiments typically depend on the experimental design and research objectives.